Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Kirsten Mundt"'
Autor:
Ewan Hunter, Ronald McCord, Aroul S. Ramadass, Jayne Green, Jurjen W. Westra, Kirsten Mundt, Alexandre Akoulitchev
Publikováno v:
Translational Medicine Communications, Vol 5, Iss 1, Pp 1-13 (2020)
Abstract Background Diffuse large B-cell lymphoma (DLBCL) is a heterogenous blood cancer, but can be broadly classified into two main subtypes, germinal center B-cell-like (GCB) and activated B-cell-like (ABC). GCB and ABC subtypes have very differen
Externí odkaz:
https://doaj.org/article/dd1dbd6712ab427ab6b8e4a4c9f5aa08
Autor:
Kirsten Mundt
Publikováno v:
Cultural Studies. 34:489-492
Catherine Walsh and Walter Mignolo's On decoloniality is an un-disciplinary read, challenging the foundational logic of Western knowledge production. Building upon Anibel Quijano's work on colonial...
Autor:
Alexandre Akoulitchev, Kirsten Mundt, Ewan Hunter, Aroul Ramadass, Jayne Green, Ronald McCord, Jurjen Westra
Publikováno v:
Translational Medicine Communications, Vol 5, Iss 1, Pp 1-13 (2020)
Background Diffuse large B-cell lymphoma (DLBCL) is a heterogenous blood cancer, but can be broadly classified into two main subtypes, germinal center B-cell-like (GCB) and activated B-cell-like (ABC). GCB and ABC subtypes have very different clinica
Autor:
Kirsten Mundt, Benjamin M. Beckermann, Nastya Kassir, Christophe Schmitt, Candice Jamois, Magali Genevray, Claire Petry, Joy Yang, Doreen Anders
Publikováno v:
Blood. 136:7-8
Background: Myelosuppression, and especially severe and prolonged neutropenia, can make patients (pts) with acute myeloid leukemia (AML) susceptible to fatal infections. Idasanutlin (idasa), a MDM2 antagonist promoting p53 tumor suppressor activity,
Autor:
Christiane Pott, Laurie H. Sehn, Nathalie Spielewoy, Bruce D. Cheson, Eva Hoster, Guenter Fingerle-Rowson, Chris Harbron, E. Nicolas-Virelizier, David Belada, Brad S. Kahl, John G. Gribben, Kirsten Mundt, Britta Kehden, Elisabeth Wassner-Fritsch
Publikováno v:
Leukemia
We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus bendamustine (Benda
Autor:
Mikkel Z. Oestergaard, Umberto Vitolo, Franklin Peale, Elizabeth Punnoose, Eugene Kim, Randy D. Gascoyne, Richard Bourgon, An D Do, Anja Mottok, Maurizio Martelli, Guiyuan Lei, F. Javier Munoz, Liping Zhang, Laurie H. Sehn, Marek Trnĕný, Gilles Salles, Edith Szafer-Glusman, Kirsten Mundt, John F. Seymour, Pedro Farinha
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:267-278.e10
Introduction The prognostic value of B-cell lymphoma 2 (BCL2) expression in de novo diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy is of interest to define a target patient population for clinical development of BCL2 inhibitors
Autor:
Luciano J. Costa, Andrew D. Zelenetz, Mehrdad Mobasher, Charlotte Vignal, Günter Fingerle-Rowson, Kirsten Mundt, Deniz Sahin, Luis Fayad, Andrew M. Evens, Andres Forero-Torres, Thomas Sandmann, Alberto Bessudo, Christopher R. Flowers, Ian W. Flinn, Jeff P. Sharman, Mark S. Kaminski, Kevin Kelly, Lowell Inhorn
This study investigated the safety and efficacy of obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP) in patients with advanced diffuse large B-cell lymphoma (DLBCL) and explored the impact of cell-of-origin (COO) o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e82eac73550566d53fe3dffa391519ee
https://europepmc.org/articles/PMC6445782/
https://europepmc.org/articles/PMC6445782/
Autor:
Shamzah Araf, Wolfram Klapper, Andrea Knapp, Vindi Jurinovic, Mikkel Z. Oestergaard, Verena Passerini, Eva Hoster, Robert Marcus, Oliver Weigert, Julia Richter, Andrew Davies, Jude Fitzgibbon, Wolfgang Hiddemann, Kirsten Mundt, Michael Herold, Michael Unterhalt
Publikováno v:
Blood. 134:122-122
Introduction : We have previously shown that a clinicogenetic risk model called the m7- Follicular Lymphoma (FL) International Prognostic Index (m7-FLIPI), which includes the mutation status of 7 genes (EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP, and
Autor:
Amrita Krishnan, Eric W. Humke, Jacqueline McBride, Andrew Polson, Sikander Ailawadhi, Asher Chanan-Khan, Ralph V. Boccia, James Scott McClellan, Jochen Brumm, Seema Singhal, Vanitha Ramakrishnan, Kyu Hong, Douglas D. Leipold, A. Keith Stewart, Quyen Shon-Nguyen, Kirsten Mundt, Jesus G. Berdeja, Ruben Niesvizky, Divya Samineni, Manish R. Patel, Yuanyuan Xiao
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 9, Iss 2, Pp 1-12 (2019)
Blood Cancer Journal, Vol 9, Iss 2, Pp 1-12 (2019)
FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent.
Autor:
Michael Herold, Christopher Pocock, Nathalie Danesi, Helen Brown, Jiri Mayer, Robert Marcus, Eva Hoster, Britta Kehden, Ann Janssens, Michael Kneba, Tina Nielsen, Richard van der Jagt, Wolfgang Hiddemann, Andrea Knapp, Christiane Pott, Kirsten Mundt, Michael Unterhalt
Publikováno v:
Blood. 132:396-396
Introduction: Minimal residual disease (MRD) status reflects depth of response and informs prognosis after first-line therapy in patients (pts) with follicular lymphoma (FL). In the GALLIUM study (NCT01332968), the primary endpoint of investigator (I